BioGerm wholly acquires Kaicheng Bio to enter the biochemical field

Recently, Shanghai BioGerm Medical Technology Co., Ltd. reached a strategic consensus and completed the signing of a contract, in which BioGerm will formally enter the biochemical diagnostic field by wholly acquiring Kaisheng Biology.

As a professional manufacturer of biochemical in vitro diagnostic reagents in China, Kaicheng Bio currently has 80+ tests in 11 categories, including liver function, kidney function, glucose metabolism, lipids, cardiac muscle, pancreas, electrolytes, thrombosis and hemostasis, rheumatology and immunity, and special proteins. Among them, calcitoninogen, neutrophil gelatinase-related lipid transport protein, homocysteine, myoglobin, troponin I, glycocholic acid, glycated albumin, etc. are all recommended products of the company, which largely meet the needs of clinical medical tests and have gradually formed a nationwide marketing and service network.

As an important part of in vitro diagnostics, biochemical diagnostics is the most commonly used in vitro diagnostic modality in clinical practice. BioGerm` s acquisition of Kaisheng Bio, which has independent R&D strength and rich reagent menu, will help its rapid entry in the biochemical diagnostic market and is an important part of the company's important strategic layout.

About BioGerm

Shanghai BioGerm Medical Technology Co., Ltd., founded in March 2017, specializes in the R&D, production and sales of diagnostic reagents and equipment related to infectious pathogens. The Company also offers diversified services in terms of sequencing, scientific research and medical testing, providing customers with total solutions according to their specific needs.

Headquartered in Shanghai, the Company has an R&D center, a manufacturing center, a marketing center, a technical service center and a comprehensive management center, which cover a gross area of over 50,000m2. Besides, the Company has R&D sub-centers in Beijing and Guangzhou, a production-research integration base, and branches in many important cities/regions.

We survive on quality and innovate for further development. The Company has set up five major technology platforms - Fluorescent PCR Platform, Isothermal Nucleic Acid Amplification Platform, Immunity Platform, Instrument Manufacturing Platform and Sequencing Platform. As of March 2023, BioGerm has obtained certificate and medical device licenses from about 10 countries, including 28 in China, 68 in the EU CE, 3 in Saudi Arabia, 2 in Brazil, and 1 in Russia etc. The company is a high-tech enterprise in China and has won many government honors, including Shanghai "SRDI" Enterprise, Shanghai Patent Work Pilot Demonstration Unit, Shanghai 2022 Industry-Education Integration Enterprise, etc.

The Company has developed more than 500 types of reagents and instruments for nucleic acid testing and antigen/antibody rapid test on pathogens. 

BioGerm upholds the core values of customer-first, innovation-driven, gratitude and altruism, is committed to serving more than 5,500 end users, winning wide acclaim from them.